Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lawmakers Plan Bill In Response To GAO Power Morcellator Report

Executive Summary

Several US House lawmakers are drafting a bill in response to a Government Accountability Office report finding that FDA's Medical Device Reporting system has shortcomings that may have missed adverse events for laparoscopic power morcellators. The devices have been linked to an increased risk of spreading cancer in women undergoing fibroid surgery.

Advertisement

Related Content

Pilot Of New US Evaluation System Will Include At Least Two Devices
FDA Turns Adverse-Event Reporting Scrutiny On Hospitals
Reps. Fitzpatrick, Slaughter Introduce Device Defect Reform Bills
Lawmaker Asks FDA To Launch Criminal Inquiry Into Power Morcellators
Ob/Gyn Specialists Ask FDA To Soften Power Morcellation Warning
FDA Puts Black Box Warning On Power Morcellators With Immediately-In-Effect Guidance
FDA Panel Advises Patient Consent With Power Morcellators To Warn Of Cancer Risk

Topics

Advertisement
UsernamePublicRestriction

Register

MT104427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel